A report raises urgent governance concerns around AI systems that can design and run thousands of biological experiments with minimal human involvement, arguing that oversight mechanisms are struggling to keep pace. The piece characterizes rapid progress in autonomous lab workflows, while noting that governance layers—intended to control how such capabilities are used—have not matured at the same speed. The question is not whether automation is feasible, but whether the guardrails match the scale and speed of experimentation. For biotech stakeholders, the issue cuts across platform strategy, lab operations, and compliance planning, especially as discovery teams move toward automated “closed-loop” cycles. The development also adds pressure for clearer standards on responsible deployment, documentation, and monitoring for AI-augmented wet-lab systems.